Research Article
Event-Related Potentials in Parkinson’s Disease Patients with Visual Hallucination
Table 1
Characteristics in PD-H, PD-NH, and controls.
| | PD-H | PD-NH | Controls | p | | |
| Age1, years | 67.79 ± 7.93 | 66.36 ± 9.68 | 68.29 ± 6.83 | 0.753 | Women1, n (%) | 5 (36) | 7 (28) | 10 (59) | 0.107 | Education1, y | 9.27 ± 6.65 | 10.88 ± 4.16 | 12.16 ± 3.32 | 0.245 | Disease duration2, y | 11.73 ± 6.41 | 6.20 ± 4.86 | n/a | 0.007 | Duration of levodopa2, y | 8.44 ± 5.78 | 3.04 ± 3.57 | n/a | 0.004 | H&Y2 | 2.65 ± 0.89 | 1.52 ± 0.65 | n/a | <0.001 | MMSE1 (score) | 27.73 ± 2.20 | 27.58 ± 1.36 | 28.41 ± 1.37 | 0.472 | HDI1 (score) | 5.00 ± 4.67 | | 0.25 ± 0.79 | <0.001 |
| UPDRS-III motor2 (score) | 27.92 ± 13.00 | 14.20 ± 8.42 | n/a | <0.001 | Levodopa-equivalent dose | 863.8 ± 390.6 | 311.2 ± 160.5 | n/a | 0.08 |
|
|
PD-H: PD patients with visual hallucinations; PD-NH: PD patients without visual hallucinations; H&Y: Hoehn and Yahr stage; HDI: Hamilton depression index; UPDRS: Unified Parkinson’s Disease Rating Scale; n/a: not available. p: p value, ; by 1ANOVA 2t-test.
|